Drugs / Sym022
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04641871 | Oct 2020 → Jun 2024 | metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT03489369 | May 2018 → Jan 2020 | lymphoma, metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT03311412 | Nov 2017 → Mar 2022 | lymphoma, metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03311412 ↗ |
| Known as | Sym-022 (anti-lag-3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298115 ↗ |
| Action | Inhibit | “blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction” NCT03311412 ↗ |
| Route | Intravenous | “each by IV infusion” NCT03311412 ↗ |
| Target | LAG3 | “Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction” NCT03489369 ↗ |